An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hypogonadism

Interventions

DRUG: Androxal

Sponsor

Repros Therapeutics Inc.

Collaborators

[object Object]